AC Immune (ACIU)
(Delayed Data from NSDQ)
$2.37 USD
-0.01 (-0.42%)
Updated Apr 24, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
AC Immune [ACIU]
Reports for Purchase
Showing records 1 - 20 ( 62 total )
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Preclinical AD Trial Analysis Needs Different Approach to Understand Treatment Effects
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Live from AD/PD 2024 Lisbon-Mechanistic Insights on ARIA Exploring the Role of Classical Complement Pathway Activation
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
AC Immune Shifts Gear, Focuses on Three Active Immunization Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Expecting an Active Dose That Shows Signs of Amyloid Reduction in ABATE; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
All Eyes on ACI-24.060s Safety, Immunogenicity, and PET Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Key Takeaways from CTAD 2023¯Implications for the Next Generation Anti-AmyloidsThis report contains brief updates on the following: ABOS, ACIU, ALEC, BIIB, DNLI, PRTA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Abeta PET and Alpha-Synuclein SAA Might Help Understand Vaccine Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Expectations from the Phase 1b/2 ABATE Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Abeta PET Data Might Determine future of ABATE; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
KOL Webinar Reflects on the Current Trends in Biomarker Development in CNS Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
NfL Might be the Best Predictor of Motor Progression in PD-Takeaways from AD/PD 2023 Gothenburg
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Thoughts on the Anti Abeta Vaccine ACI-24.060; Reit. Buy and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Future of AD Therapy Might be Vaccines-Takeaways from ACI-35.030 Data Readout at CTAD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Passive Anti-Abeta Immunotherapies are Encouraging for Abeta Vaccines; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Seed for Successful PD Trial Outcome is Sown¯Takeaways From the 2022 PD Therapeutic Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
The Beginning of an Era of Anti-Amyloids and Combination Therapies in Alzheimer''s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
The Pubmed Times¯Focusing on the Need to Pull Down Toxic Oligomers
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
KOL Webinar Showcases the Strength of Vaccines Over Passive Immunization for AD and PD Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Thoughts on API ADAD Data Readout-Implications for Anti-Abeta Therapy Landscape
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Reflections on the Upcoming ACI-24.060 Phase 1b Interim Data Readout in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A